KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eli Lilly (LLY) Interest Coverage Ratio (2009 - 2012)

Eli Lilly posted quarterly Interest Coverage Ratio of 31.02 for Q1 2012, down 15.09% year-on-year from 36.53 in Q2 2011, and up 45.42% on a QoQ basis from 21.33 in Q4 2011.

Eli Lilly (LLY) has 4 years of Interest Coverage Ratio data on file, last reported at 31.02 in Q1 2012.

  • For the quarter ending Q1 2012, Interest Coverage Ratio fell 15.09% year-over-year to 31.02; the trailing twelve-month figure through Dec 2012 stood at 110.71 (up 248.05% YoY), and the FY2011 full-year result was 10.07, down 18.24% from the prior year.
  • Interest Coverage Ratio for Q1 2012 stood at 31.02, up from 21.33 in the prior quarter.
  • Across five years, Interest Coverage Ratio topped out at 36.53 in Q1 2011 and bottomed at 21.33 in Q4 2011.
  • The 4-year median for Interest Coverage Ratio is 33.57 (2010), against an average of 31.74.
  • The widest annual swing landed in 2010, when Interest Coverage Ratio soared 44.78%; it then slumped 36.41% in 2011.
  • A 4-year view of Interest Coverage Ratio shows it stood at 23.2 in 2009, then surged by 44.57% to 33.54 in 2010, then plunged by 36.41% to 21.33 in 2011, then soared by 45.42% to 31.02 in 2012.
  • The last three Interest Coverage Ratio figures came in at 31.02 (Q1 2012), 21.33 (Q4 2011), and 35.24 (Q3 2011), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Interest Cover (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn -
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 23.39
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn -
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 4.06
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 10.78
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn -
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2012 31.02
Dec 31, 2011 21.33
Sep 30, 2011 35.24
Jun 30, 2011 35.23
Mar 31, 2011 36.53
Dec 31, 2010 33.54
Sep 30, 2010 32.31
Jun 30, 2010 33.59
Mar 31, 2010 35.36
Jun 30, 2009 23.20